NASDAQ:APVO Aptevo Therapeutics (APVO) Stock Forecast, Price & News $1.56 0.00 (0.00%) (As of 06/1/2023 ET) Add Compare Share Share Today's Range$1.51▼$1.6150-Day Range$1.56▼$2.0852-Week Range$1.51▼$7.20Volume73,654 shsAverage Volume66,690 shsMarket Capitalization$11.37 millionP/E RatioN/ADividend YieldN/APrice Target$13.00 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media Aptevo Therapeutics MarketRank™ ForecastAnalyst RatingN/A0.00 Rating ScoreUpside/Downside728.0% Upside$13.00 Price TargetShort InterestHealthy0.97% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthDecreasingFrom ($3.24) to ($4.91) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.64 out of 5 starsMedical Sector1729th out of 1,980 stocksPharmaceutical Preparations Industry869th out of 978 stocks 2.0 Analyst's Opinion Price Target Upside/DownsideAccording to analysts' consensus price target of $13.00, Aptevo Therapeutics has a forecasted upside of 728.0% from its current price of $1.57.Amount of Analyst CoverageAptevo Therapeutics has received no research coverage in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted0.97% of the outstanding shares of Aptevo Therapeutics have been sold short.Short Interest Ratio / Days to CoverAptevo Therapeutics has a short interest ratio ("days to cover") of 1.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Aptevo Therapeutics has recently decreased by 47.60%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldAptevo Therapeutics does not currently pay a dividend.Dividend GrowthAptevo Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for APVO. Previous Next 2.5 News and Social Media Coverage News SentimentAptevo Therapeutics has a news sentiment score of 0.50. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Aptevo Therapeutics this week, compared to 0 articles on an average week.MarketBeat Follows4 people have added Aptevo Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 300% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Aptevo Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 3.70% of the stock of Aptevo Therapeutics is held by insiders.Percentage Held by InstitutionsOnly 17.04% of the stock of Aptevo Therapeutics is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Aptevo Therapeutics are expected to decrease in the coming year, from ($3.24) to ($4.91) per share.Price to Book Value per Share RatioAptevo Therapeutics has a P/B Ratio of 0.49. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Aptevo Therapeutics (NASDAQ:APVO) StockAptevo Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on developing novel immunotherapies for the treatment of cancer. Its pipeline APVO436, ALG.APV-527 and APVO603 were developed based on the ADAPTIR modular protein platform technology and APVO442 was developed based on the new ADAPTIR-FLE platform technology. The ADAPTIR and ADAPTIR-FLEX are capable of generating differentiated bispecific and multi-specific antibodies with potentially unique mechanisms of action for the treatment of different types of cancer. The company was founded on February 22, 2016 and is headquartered in Seattle, WA.Read More Receive APVO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Aptevo Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address APVO Stock News HeadlinesMay 27, 2023 | americanbankingnews.comAptevo Therapeutics (NASDAQ:APVO) Research Coverage Started at StockNews.comMay 19, 2023 | americanbankingnews.comAptevo Therapeutics (NASDAQ:APVO) Coverage Initiated by Analysts at StockNews.comJune 1, 2023 | Edge On The Street (Ad)AI Getting Close to Thinking Like HumansTechnology experts working with neuroscientists have created the world's first Artificial Intelligence Network Operating System. AI can now process information like the human brain and understand the world the way humans do.May 14, 2023 | americanbankingnews.comAptevo Therapeutics Inc. (NASDAQ:APVO) Sees Large Growth in Short InterestMay 12, 2023 | americanbankingnews.comAptevo Therapeutics (NASDAQ:APVO) Coverage Initiated at StockNews.comMay 11, 2023 | finance.yahoo.comAptevo Therapeutics Reports 1Q23 Financial Results and Provides Business UpdateMay 9, 2023 | americanbankingnews.comAptevo Therapeutics (APVO) Scheduled to Post Earnings on WednesdayMay 3, 2023 | americanbankingnews.comAptevo Therapeutics (NASDAQ:APVO) Now Covered by Analysts at StockNews.comJune 1, 2023 | Edge On The Street (Ad)AI Getting Close to Thinking Like HumansTechnology experts working with neuroscientists have created the world's first Artificial Intelligence Network Operating System. AI can now process information like the human brain and understand the world the way humans do.April 6, 2023 | americanbankingnews.comAptevo Therapeutics (NASDAQ:APVO) Upgraded at StockNews.comApril 1, 2023 | finance.yahoo.comAptevo Therapeutics Full Year 2022 Earnings: EPS Beats ExpectationsMarch 30, 2023 | finance.yahoo.comAptevo Therapeutics Raises $9.6 Million in Non-Dilutive FundingMarch 30, 2023 | finance.yahoo.comAptevo Therapeutics Reports 2022 Financial Results and Provides Business UpdateJanuary 9, 2023 | finance.yahoo.comAptevo Therapeutics Files Provisional Patent for Fifth Bispecific Antibody APVO711, Intended for the Treatment of Solid TumorsDecember 20, 2022 | finance.yahoo.comAptevo Stock Jumps As Acute Myeloid Leukemia Combo Therapy Achieves 100% Clinical Benefit RateDecember 14, 2022 | benzinga.comShort Volatility Alert: Aptevo TherapeuticDecember 12, 2022 | finance.yahoo.com100% Clinical Benefit Rate Achieved in Phase 1b Trial Evaluating APVO436 in Combination with Venetoclax and Azacitidine for Venetoclax Treatment Naïve Patients with Acute Myeloid Leukemia (AML)November 10, 2022 | finance.yahoo.comAptevo Therapeutics Reports Third Quarter 2022 Financial Results and Business HighlightsNovember 9, 2022 | finance.yahoo.comAlligator Bioscience & Aptevo Therapeutics Announce Publication Highlighting ALG.APV-527 Preclinical Data in Peer-Reviewed Journal Molecular Cancer TherapeuticsNovember 3, 2022 | finance.yahoo.comAptevo Therapeutics Announces Poster Presentation at the 64th American Society of Hematology Annual Meeting and ExpositionOctober 1, 2022 | seekingalpha.comAPVO Aptevo Therapeutics Inc.September 19, 2022 | finance.yahoo.comAlligator Bioscience and Aptevo Therapeutics Announce that FDA has Issued a "May Proceed" Notification for the ALG.APV-527 INDAugust 11, 2022 | finance.yahoo.comAptevo Therapeutics Reports Second Quarter 2022 Financial Results and Business HighlightsAugust 4, 2022 | nasdaq.comZymeworks Inc. (ZYME) Reports Q2 Loss, Misses Revenue EstimatesJune 17, 2022 | msn.comAptevo Therapeutics's Return On Capital Employed OverviewJune 11, 2022 | seekingalpha.comAptevo gains after disclosing additional remission data in leukemia trialJune 9, 2022 | finance.yahoo.comAptevo Therapeutics Announces New Preliminary Remission Data on Four Additional Patients Enrolled in On-going APVO436 Dose Expansion Phase 1b Trial for the Treatment of Acute Myeloid LeukemiaSee More Headlines APVO Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart APVO Company Calendar Last Earnings5/11/2023Today6/01/2023Next Earnings (Estimated)8/10/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:APVO CUSIPN/A CIK1671584 Webwww.aptevotherapeutics.com Phone(206) 838-0500Fax206-838-0503Employees54Year Founded2016Price Target and Rating Average Stock Price Forecast$13.00 High Stock Price Forecast$13.00 Low Stock Price Forecast$13.00 Forecasted Upside/Downside+729.5%Consensus RatingN/A Rating Score (0-4)0.00 Research Coverage0 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$8.03 million Net MarginsN/A Pretax Margin225.24% Return on Equity-102.29% Return on Assets-58.61% Debt Debt-to-Equity RatioN/A Current Ratio4.91 Quick Ratio4.91 Sales & Book Value Annual Sales$3.11 million Price / Sales3.67 Cash FlowN/A Price / Cash FlowN/A Book Value$3.19 per share Price / Book0.49Miscellaneous Outstanding Shares7,290,000Free Float7,020,000Market Cap$11.43 million OptionableOptionable Beta5.33 Social Links Key ExecutivesMarvin L. WhitePresident, Chief Executive Officer & DirectorJeffrey G. LamotheChief Operating Officer & Executive Vice PresidentDaphne L. TaylorChief Financial Officer & Senior Vice PresidentDirk HuebnerChief Medical OfficerMiriam Weber MillerInvestor Relations ContactKey CompetitorsDominariNASDAQ:DOMHSonnet BioTherapeuticsNASDAQ:SONNSigilon TherapeuticsNASDAQ:SGTXEterna TherapeuticsNASDAQ:ERNAMonopar TherapeuticsNASDAQ:MNPRView All CompetitorsInstitutional OwnershipRenaissance Technologies LLCSold 10,500 shares on 5/12/2023Ownership: 0.759%View All Institutional Transactions APVO Stock - Frequently Asked Questions What is Aptevo Therapeutics' stock price forecast for 2023? 0 equities research analysts have issued twelve-month price targets for Aptevo Therapeutics' stock. Their APVO share price forecasts range from $13.00 to $13.00. On average, they anticipate the company's share price to reach $13.00 in the next year. This suggests a possible upside of 729.5% from the stock's current price. View analysts price targets for APVO or view top-rated stocks among Wall Street analysts. How have APVO shares performed in 2023? Aptevo Therapeutics' stock was trading at $2.32 at the start of the year. Since then, APVO stock has decreased by 32.4% and is now trading at $1.5673. View the best growth stocks for 2023 here. Are investors shorting Aptevo Therapeutics? Aptevo Therapeutics saw a drop in short interest in May. As of May 15th, there was short interest totaling 71,000 shares, a drop of 47.6% from the April 30th total of 135,500 shares. Based on an average daily volume of 53,100 shares, the days-to-cover ratio is currently 1.3 days. View Aptevo Therapeutics' Short Interest. When is Aptevo Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 10th 2023. View our APVO earnings forecast. How were Aptevo Therapeutics' earnings last quarter? Aptevo Therapeutics Inc. (NASDAQ:APVO) released its earnings results on Thursday, May, 11th. The biotechnology company reported $0.26 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.19) by $1.45. What other stocks do shareholders of Aptevo Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Aptevo Therapeutics investors own include Advanced Micro Devices (AMD), Amarin (AMRN), AVEO Pharmaceuticals (AVEO), Alibaba Group (BABA), Micron Technology (MU), OPKO Health (OPK), AbbVie (ABBV), Aurinia Pharmaceuticals (AUPH), BioXcel Therapeutics (BTAI) and T2 Biosystems (TTOO). What is Aptevo Therapeutics' stock symbol? Aptevo Therapeutics trades on the NASDAQ under the ticker symbol "APVO." Who are Aptevo Therapeutics' major shareholders? Aptevo Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Renaissance Technologies LLC (0.76%). View institutional ownership trends. How do I buy shares of Aptevo Therapeutics? Shares of APVO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Aptevo Therapeutics' stock price today? One share of APVO stock can currently be purchased for approximately $1.57. How much money does Aptevo Therapeutics make? Aptevo Therapeutics (NASDAQ:APVO) has a market capitalization of $11.43 million and generates $3.11 million in revenue each year. How can I contact Aptevo Therapeutics? Aptevo Therapeutics' mailing address is 2401 4TH AVENUE SUITE 1050, SEATTLE WA, 98121. The official website for the company is www.aptevotherapeutics.com. The biotechnology company can be reached via phone at (206) 838-0500, via email at jurchisons@apvo.com, or via fax at 206-838-0503. This page (NASDAQ:APVO) was last updated on 6/1/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aptevo Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.